23 results
The purpose of this study is to evaluate the safety and preliminary efficacy of avelumab in combination with M9241in subjects with metastatic or locally advanced unresectable solid tumors. This dose escalation study will establish a safe dose of…
We aim to get insight in the actual quality of oncofertility care in young females with cancer. With this insight we can identify barriers and develop a strategy to improve quality of oncofertility care and thereby quality of life for young female…
Primary Objective:* To evaluate ORR of avelumab in combination with talazoparib, in patients with locally advanced or metastatic solid tumors harboring BRCA1, BRCA2 or ATM defect.Secondary Objective:* To assess the overall safety and tolerability of…
Primary objectives: To evaluate safety of ZED88082A in combination with CED88004S. To determine appropriate ZED88082A/CED88004S dosing and PET imaging time-points. To evaluate pharmacokinetics (PK) of ZED88082A/CED88004S in patients before and…
Objective: To assess whether early changes in hypoxia between baseline and in the (end of the) second week of proton therapy are predictive for time-to-local recurrence in patients with HNSCC (primary). Secondary objectives include: to compare the…
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Study (MOMENTUM) aims to accelerate the technical and clinical development of Anatomic and Functional MRGRT and facilitate the evidence-based introduction of the MR-Linac into…
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…
This study has been transitioned to CTIS with ID 2022-502668-20-00 check the CTIS register for the current data. PHASE 1 OBJECTIVES:Primary:To determine the safety of oral larotrectinib , including dose-limiting toxicity (DLT), in pediatric patients…
To assess the pharmacokinetics of various cytotoxic agents (carboplatin, cisplatin, cytarabine, dactinomycin, daunorubicin, doxorubicin, etoposide, methotrexate and vincristine) and tyrosine kinase inhibitors (ALK inhibitors, MEK inhibitors, BCR-ABL…
Primary Objectives:Dose escalation (Part 1)Part 1A (SAR439459 monotherapy)-To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with…
The aim of the study is to develop PD-L1 PET/CT imaging in patients with advanced HNSCC to non-invasively image PD-L1 expression in tumours and to determine the correlation with response to durvalumab. The studie will be divided into 2 parts:1:…
4.1 Primary Objective• To determine the MTD and to establish the safety profile of enapotamab vedotin in a mixed population of patients with specified solid tumors. 4.2 Secondary Objectives• To evaluate the safety laboratory parameters of enapotamab…
Primary objective:To investigate whether MR-only radiotherapy in prostate and rectal cancer patients is at least non-inferior in terms of position verification performed by a registration between the pCT and CBCT instead of the CT.Secondary…
With this prospective study, we aim to investigate the relationship between skeletal muscle mass and cisplatin plasma pharmacokinetics in HNSCC patients treated with conventional primary and postoperative CRT with cisplatin. It is designed to be a…
The MR-Linac Technical Feasibility Protocol For Development of MR-guided Adaptive Radiation Therapy.
Primary: To test the feasibility of multiple techniques / software for MR-guided adaptive radiation therapy on the Elekta Unity MRL.Secondary: To register acute grade >= 3 toxicity.
This study has been transitioned to CTIS with ID 2024-510984-52-00 check the CTIS register for the current data. Main Objective : - Dose escalation part: To determine the recommended phase 2 dose (RP2D) of Debio 0123 when administered in combination…
Primary: Part 1: Safety and tolerability. Determine the MTD and/or RP2D of MAK683.Part 2: Anti-tumor activity of MAK683.Secondary: Part 1: Anti-tumor activity. Pharmacodynamics (PD). Pharmacokinetics (PK).Part 2: Safety and tolerability. PK, PD.
Phase1: To characterize the safety and tolerability of isatuximab in combination with atezolizumab in participants with unresectable hepatocellular carcinoma (HCC), platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and…
The purpose of this study is to investigate how quickly and to what extent rogaratinib is absorbed, distributed, metabolized (broken down) and eliminated from the body (this is called pharmacokinetics). Rogaratinib will be labelled with 14 Carbon (…
To assess the kinetics of ctDNA in blood and saliva before, during and after definitive radiotherapy for HNSCC and to determine the prognostic value of ctDNA as predictor for treatment response in respect to conventional imaging.